{"id":"NCT02607800","sponsor":"Gilead Sciences","briefTitle":"Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy","officialTitle":"A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Naïve Subjects With Chronic HCV Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-16","primaryCompletion":"2016-10-10","completion":"2017-01-11","firstPosted":"2015-11-18","resultsPosted":"2017-11-08","lastUpdate":"2019-03-05"},"enrollment":943,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"SOF/VEL/VOX","otherNames":["GS-7977/GS-5816/GS-9857","Vosevi®"]},{"type":"DRUG","name":"SOF/VEL","otherNames":["GS-7977/GS-5816","Epclusa®"]}],"arms":[{"label":"SOF/VEL/VOX","type":"EXPERIMENTAL"},{"label":"SOF/VEL 12 weeks","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objectives of this study are to compare the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed dose combination (FDC) for 8 weeks with that of SOF/VEL FDC for 12 weeks in direct-acting antiviral-naive participants with chronic hepatitis C virus (HCV) infection.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"SOF/VEL/VOX 8 Weeks","deltaMin":95.2,"sd":null},{"arm":"SOF/VEL 12 Weeks","deltaMin":98.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":93,"countries":["United States","Australia","Canada","France","Germany","New Zealand","Puerto Rico","United Kingdom"]},"refs":{"pmids":["28390869"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":501},"commonTop":["Headache","Fatigue","Diarrhoea","Nausea","Asthenia"]}}